Sensitizing <i>Staphylococcus aureus</i> to antibacterial agents by decoding and blocking the lipid flippase MprF.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35044295.
- Also identified by DOI 10.7554/eLife.66376 and PMC identifier 8806190.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The pandemic of antibiotic resistance represents a major human health threat demanding new antimicrobial strategies. Multiple peptide resistance factor (MprF) is the synthase and flippase of the phospholipid lysyl-phosphatidylglycerol that increases virulence and resistance of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and other pathogens to cationic host defense peptides and antibiotics. With the aim to design MprF inhibitors that could sensitize MRSA to antimicrobial agents and support the clearance of staphylococcal infections with minimal selection pressure, we developed MprF-targeting monoclonal antibodies, which bound and blocked the MprF flippase subunit. Antibody M-C7.1 targeted a specific loop in the flippase domain that proved to be exposed at both sides of the bacterial membrane, thereby enhancing the mechanistic understanding of bacterial lipid translocation. M-C7.1 rendered MRSA susceptible to host antimicrobial peptides and antibiotics such as daptomycin, and it impaired MRSA survival in human phagocytes. Thus, MprF inhibitors are recommended for new antivirulence approaches against MRSA and other bacterial pathogens.
Medical subject headings
- Aminoacyltransferases
- Anti-Bacterial Agents
- Bacterial Proteins
- Daptomycin
- Staphylococcus aureus